Sep. 5: PAD Common in HIV-Positive Patients Over 50
	Peripheral arterial disease (PAD) was found in just over 10 percent of a group of HIV-positive patients older than 50, according to the authors of a study published in the September issue of AIDS Research and Human Retroviruses.

	Sep. 4: Genes, Not Race, Should Guide Antiretroviral Treatment
	A person’s genetic sequence, and not his or her race, should guide scientists and health care providers in the design of clinical trials and treatment decisions with antiretroviral (ARV) drugs such as efavirenz (found in Sustiva and Atripla), according to a review article published in the September 1 issue of AIDS.

	Sep. 3: Vistide Not Effective in Treating PML
	The addition of Vistide (cidofovir) to antiretroviral (ARV) therapy did not slow disease progression or prevent death in HIV-positive people with progressive multifocal leukoencephalopathy (PML), according to a study in the September 1 issue of AIDS.

	Sep. 2: Norvir and Heart Conduction Disturbances
	People taking 400 mg or more of Norvir (ritonavir) twice-daily may have delayed conduction of electrical charges in their hearts, according to a notice from the U.S. Food and Drug Administration (FDA) detailing revisions to Norvir’s prescribing information.

	Sep. 2: Worsening Depression in Four Patients on Isentress
	Four patients who switched to a regimen containing Isentress (raltegravir) had a temporary worsening of preexisting depression, according to a letter in the September 12 issue of AIDS that was reported by aidsmap.com.

	Aug. 29: Hormonal Contraceptives and HIV Disease Progression
	There is a possible link between hormonal contraceptives and faster HIV disease progression, according to a research review article in the October 1 issue of Clinical Infectious Diseases (CID).